• Therapeutic strategies and diagnostic pharmacology in neuromuscular disorders highlight cholinergic modulation and steroid-based interventions, spanning poliomyelitis and myasthenia gravis, with emphasis on neostigmine/prostigmine use and safety considerations [4], [10], [18], [11].

• Genetic and familial patterns emphasize heredity and phenotypic variation across dystrophies and MG, illustrated by facioscapulohumeral dystrophy inheritance, congenital MG in siblings, progressive muscular dystrophy, osseous atrophy associations, and familial periodic paralysis [2], [5], [1], [9], [15].

• Poliomyelitis-related neuromuscular dysfunction is framed by pathophysiological questions and therapeutic exploration, moving beyond classic LMN paralysis to probe muscle dysfunction and cholinergic modulation in disease [4], [6].

• Electrophysiology and neurophysiological methods provide a unifying investigative framework for neuromuscular disorders, measuring action potentials, fasciculations, and nerve-evoked changes to dissect motor system function [3], [7], [20].

• Clinical breadth of myasthenia gravis includes infant cases, ocular involvement, and dysphagia-associated presentations, illustrating MG spectrum and diagnostic/therapeutic strategies [17], [14], [12], [8], [10].